The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Developments in gastric and gastroesophageal cancer management
Samuel Klempner, MD, Massachusetts General Hospital, Boston, MA, provides an overview of advances in the management of gastric and gastroesophageal cancer (GC/GEJC). Triplet combinations incorporating existing regimens such as fluorouracil and platinum chemotherapy have shown encouraging efficacy in the KEYNOTE-811 trial (NCT03615326). Discovery of novel biomarkers such as FGFR2 will additionally enable patients access to efficacious treatment, and findings from the KEYNOTE-585 (NCT03221426) and CheckMate 577 (NCT02743494) trials have shown promising results for perioperative immunotherapy. The INFINITY (NCT04817826) and GERCOR NEONIPIGA (NCT04006262) studies have also provided updates in microsatellite instability high GC/GEJC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
